Clinical Biochemistry - McMaster Experts

publication venue for

Do instructions for at-home dried blood spot (DBS) collection affect the quality of collection? Data from the Canadian Longitudinal Study on Aging (CLSA) COVID-19 seroprevalence study 2022
Monitoring and adjusting for analytical bias in chemistry tests using longitudinal quality control (LQC) samples 2022
Applying Evidence Based Medicine in Laboratory Medicine: insight of laboratory medicine professionals worldwide 2020
Drugs of abuse quantification using LC-MS/MS 2020
Identification of therapy driven events on proteome landscape of patient matched primary-recurrent Glioblastoma for development of novel diagnostic and predictive biomarkers 2020
Investigating potential interferences in pediatric creatinine measurements methodologies amongst pediatric renal transplant recipients 2019
Method development and validation of tranexamic acid by LC-MS/MS 2019
Validation and evaluation of infliximab assay in IBD 2019
A pathway to limit AST testing 2018
Assessment of myocardial injury early after initiation of treatment in breast cancer patients using the Beckman Coulter and Abbott Diagnostics high-sensitivity cardiac troponin I tests 2018
CSCC harmonized reference intervals working group: Progress towards harmonization 2018
Comparison of NT-pro BNP and BNP commercially-available assays 2018
Development of Canadian reference intervals and confidence intervals using data mining: Application of the Arzideh statistical method 2018
Lipid reporting across Canada: current variability and proposed harmonized lipid profile and interpretive comments 2018
Reference interval studies for chemistry analytes: judgement of risk of bias and applicability 2018
Evaluation of the Roche fructosamine method on the Beckman AU400 2016
Human herpes virus-6B can be preset in POEMS syndrome 2016
Pre-analytical storage conditions may affect Abbott ARCHITECT high-sensitivity cardiac troponin I results 2016
The conundrum of evaluating lot change over multiple lots of reagent 2016
Changes in glucose concentrations in emergency department patients presenting with symptoms of acute coronary syndrome 2015
Comparison of multiplexed assessment of celiac autoantibodies to an ELISA-based method reveals good performance of a multiplexing platform 2015
Effect of glucose interference with Jaffe creatinine measurement on EGFR calculation 2015
Estrone sulfate testing: Evaluation of serum measurements by radioimmunoassay 2015
Glucose interference in Jaffe Creatinine assays: Not all assays are the same 2015
Red blood cell assay quantifying plasmalogen concentration to diagnose peroxisome disorders 2015
A REDCap database to support longitudinal follow-up of pediatric patients with inborn errors of metabolism 2014
Biotinidase deficiency: Spectrum of molecular, enzymatic and clinical information—A pilot project 2014
Building a pan-Canadian practice-based research network for inherited metabolic diseases: The first two years of the Canadian Inherited Metabolic Diseases Research Network (CIMDRN) 2014
Development and validation of reversed phase chromatography method for acylcarnitine analysis and its application to second tier newborn screening for inborn organic acid disorders 2014
Metabolic clinic atlas: Organization of care for pediatric metabolic patients in Canada 2014
Metabolomics for discovery of biomarkers for cystic fibrosis: Towards MS-based primary screening methods with improved positive predictive value 2014
Metabolomics for improved patient stratification in cystic fibrosis: Characterization of the sweat metabolome 2014
Multiplexed separations for rapid confirmatory testing of screen-positive inborn errors of metabolism 2014
Rapid confirmatory testing of thyroxine status by multi-segment capillary electrophoresis-mass spectrometry with chemical derivatization 2014
The importance of challenging phenylalanine (Phe) tolerance in patients with phenylketonuria (PKU) 2014
Towards a clinical trial of lentivirus-mediated gene therapy for Fabry disease: In vitro patient cell mobilization and transduction outcomes 2014
Assessing the long-term stability of total bilirubin protected from light under refrigerated conditions 2014
Assessment of galectin-3, N-terminal pro-brain natriuretic peptide and inflammatory cytokines in patients with myocardial injury after initiation of adjuvant trastuzumab therapy 2014
Establishment of pediatric reference intervals for galectin-3 on the Abbott ARCHITECT using healthy community children from the CALIPER study 2014
Evaluation of hemoglobin J-Baltimore interference on HbA1c measurement using capillary electrophoresis 2014
Prevalence of known and unknown diabetes in emergency department patients presenting with symptoms of acute coronary syndrome 2014
Reactivity of macroprolactin in two widely used commercial prolactin immunoassays 2014
The diagnostic role of B-type natriuretic peptide in pediatric populations: A systematic review 2014
The utility of galectin-3 and high-sensitivity cardiac troponin assays to predict short-term serious outcomes in patients presenting early after chest-pain onset 2014
Validation and evaluation of fecal calprotectin assays in pediatric inflammatory bowel disease 2014
A biomarker panel for early identification of cardiac outcomes in a non-selected emergency department chest pain population 2012
Assessing different population-based troponin T 99th percentiles for women in labor 2012
Cardiac troponin T concentrations 30days post myocardial infarction: Results of a small prospective observational study 2012
Early serial measurements of myeloperoxidase, a sensitive cardiac troponin I and high-sensitivity cardiac troponin T in patients presenting within 6hours of chest pain onset 2012
Fatty acid binding protein and cardiac troponin I for the early rule-out of myocardial infarction in patients presenting with chest pain 2012
High sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide in healthy Canadian children 2012
Incorporating both absolute and relative change in high-sensitivity cardiac troponin T concentrations for an early diagnosis of myocardial infarction 2012
Lithium overdose associated acute thyrotoxicosis due to silent thyroiditis 2012
Temperature control for cryoglobulin sample collection 2012
Ultra performance liquid chromatography–tandem mass spectrometry determination of tryptophan metabolites 2012
A clinically sensitive cardiac troponin I assay (AccuTnI) versus the high sensitive cardiac troponin T assay to predict early serious cardiac outcomes in patients with potential acute coronary syndrome 2011
A comparison between the different versions of the Beckman coulter cardiac troponin I assay 2011
An approach for comparability testing of 20 core clinical chemistry analytes measured between identical Roche P-modular platforms 2011
Comparison between Abbott Precision Xceed Pro (PXP) and Nova Statstrip (StatStrip) glucose meters in neonates 2011
Comparison of angiogenic growth factors assays using a research mulitplex platform versus clinical platforms in patients with chest pain 2011
Comparison of cytokine biomarker performance across immunoassay platforms 2011
Method verification and comparison of beta-hydroxy-butyrate assay by olympus AU400 with 560 express plus analyzer 2011
Method verification and comparison of urine oxalate assay by Olympus AU400 with 560 express plus analyzer 2011
NT-proBNP measurement using a multiplex platform in cancer and chest pain populations 2011
Root cause analysis of delays to discharge for patients held for serial cardiac troponin levels 2011
The prevalence of preoperative elevations in troponin T above the 99th percentile using the troponin T high sensitive assay in patients undergoing noncardiac surgery 2011
Time from urine collection to urinalysis – Is four hours an acceptable delay for samples at room temperature? 2011
Vitamin D and cognition: A meta-analysis 2011
Evaluation of the Abbott Precision Xceed Pro (PXP)® glucose monitor for neonatal hypoglycemia 2011
Assessing analytical variation and the significant change limit for total CO2 measurement in uncapped tubes 2010
Biospecimen collection, processing and storage protocol for the Canadian Longitudinal Study on Aging (CLSA) 2010
Comparison between multiplex immunoassay and immunofluorescence methods in detection of anti-nuclear antibodies 2010
Early changes in biomarkers determined by LC/MS/MS and ELISA based methods in a phase I/II study assessing an anti-metastatic agent 2010
Early detection of change in concentration by a research high sensitivity troponin I (hs-cTNI) assay and health outcomes at 30days in a chest pain population 2010
Factors affecting screen completion in two forms of integrated prenatal screening for Down syndrome in the safer study 2010
Roche acetaminophen assay negative bias at low concentrations is imprvoved using the TDM diluent as the zero calibrator 2010
Analytical evaluation of C-peptide immunoassay on Immulite 2500 2008
Assessment of the use of the 99th percentile cut-off for myocardial injury on the Abbott Architect STAT Troponin-I assay 2008
Evaluation of a commercially available carbohydrate deficient transferrin kit to detect β2-transferrin in cerebrospinal fluid using capillary electrophoresis 2008
Pilot study assessing the utility of an adhesion array and high-sensitivity cytokine array as surrogate biomarkers in ovarian cancer 2008
Sex differences in pregnancy associated plasma protein-A (PAPP-A) concentrations in patients with acute coronary syndromes 2008
Utility of monitoring mycophenolic acid in solid organ transplant patients 2008
Assessment of the validity of self-reported versus quantitative measures for population and public health planning 2008
Cardiovascular risk identification in population health by biological measures 2008
Proteomic profiling of plasma apolipoprotein B 2008
Reproducibility of oral glucose tolerance test derived parameters in obese youth 2008
Stability of therapeutic drugs in heparin plasma with and without gel seperator 2008
Time-related profile of cell adhesion molecules, NT-proBNP and troponin T following chest pain onset in an emergency department population 2008
Uptake and overall performance of multiple new down syndrome screening protocols introduced coincidentally 2008
Urine amino acid screening by liquid chromatography/mass spectrometry 2008
Adiponectin oligomers in obese children 2006
Age dependency of pediatric random urine analytes calcium, phosphate, uric acid, oxalate, citrate and amino acids 2006
Brain type carnosinase: A potential serum biomarker of dementia 2006
Identification of heparin binding proteins isolated from cell membranes by proteomic analysis 2006
Performance characteristics of BNP and NT-proBNP in the diagnosis of heart failure: A systematic review of the evidence 2006
Proteomic analysis to identify ischemia-modified albumin 2006
Variation in troponin T in stable outpatient hemodialysis patients 2006
Regulation of apolipoprotein B biogenesis in human hepatocytes: Posttranscriptional control mechanisms that determine the hepatic production of apolipoprotein B-containing lipoproteins 1995
CLINICAL-ASSESSMENT OF A SIMULTANEOUS RADIOIMMUNOASSAY (RIA) FOR FREE-THYROXINE (FT4) AND THYROTROPIN (TSH) IN THE DIAGNOSIS OF THYROID-DISORDERS 1987
SENSITIVE THYROTROPIN (TSH) ASSAY - IS IT WORTH DOING AS A SCREENING-TEST FOR THYROID STATUS 1987
Colorectal spirochetosis: report of 3 cases 1984
Fine needle aspiration biopsy cytology of lymph nodes 1984
REDUCED HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN ARTERIOSCLEROTIC DEMENTIA OF THE AGED 1984
UROLITHIASIS IN A LARGE KINDRED DEFICIENT IN ADENINE PHOSPHORIBOSYLTRANSFERASE (APRT) 1983
DETECTION OF ISCHEMIC MYOCARDIAL INJURY IN PATIENTS WITH NORMAL OR SLIGHT ELEVATIONS IN, CK AND ASAT ACTIVITIES 1981
COMPARISON OF METHODS FOR MEASURING IMMUNOGLOBULINS AND C-3 1978
BIOCHEMICAL AND CLINICAL DIAGNOSIS OF MYOCARDIAL-INFARCTION 1977
SERUM FERRITIN VERSUS SERUM IRON AND IRON-BINDING IN EVALUATION OF IRON-DEFICIENCY ANEMIA 1977
A national study to evaluate analytical performance specifications for high-sensitivity cardiac troponin assays
Analytical validation of the Thermo Fischer Scientific B center dot R center dot A center dot H center dot M center dot S KRYPTOR (R) soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) assays in a North American setting
Multisite evaluation of high-sensitivity cardiac Troponin T with patient pools on different Roche analyzers: Interim report on observed components of variance
Multisite testing with different high-sensitivity cardiac troponin I assays in the normal range and near the 99th percentiles
Imprecision of high-sensitivity cardiac troponin assays at the female 99th-percentile. 125:110731-110731. 2024
Development of a second-tier method for C4, C5 and C2 acylcarnitine analysis in plasma. 123:110698-110698. 2024
Establishing acceptable variation between instruments with dry chemistry methodology. 120:110647-110647. 2023
Performance of saliva compared with nasopharyngeal swab for diagnosis of COVID-19 by NAAT in cross-sectional studies: Systematic review and meta-analysis. 117:84-93. 2023
Storage conditions, sample integrity, interferences, and a decision tool for investigating unusual high-sensitivity cardiac troponin results. 115:67-76. 2023
Current use of bone turnover markers in the management of osteoporosis. 109-110:1-10. 2022
Combination of antibody tests against SARS-CoV-2 for health care workers after vaccination. 101:54-55. 2022
Clinical chemistry score misses fewer deaths as compared to troponin T alone in a United States emergency department population. 95:91-92. 2021
Analysis of serum tranexamic acid in patients undergoing open heart surgery. 87:74-78. 2021
Canadian society of clinical chemists (CSCC) interim consensus guidance for testing and reporting of SARS-CoV-2 serology. 86:1-7. 2020
Emerging key laboratory tests for patients with COVID-19. 81:13-14. 2020
Clinical evaluation of Ortho Clinical Diagnostics high-sensitivity cardiac Troponin I assay in patients with symptoms suggestive of acute coronary syndrome. 80:48-51. 2020
Approaching 2020 acuity for high-sensitivity cardiac troponin assays in Clinical Biochemistry. 78:1-3. 2020
High-sensitivity cardiac troponin testing during and after ACS: Complexed or not?. 73:32-34. 2019
A heterophile antibody affecting a contemporary but not a high-sensitivity cardiac troponin assay. 71:72-73. 2019
Analytical characterization of the Siemens Dimension EXL high-sensitivity cardiac troponin I assay. 69:52-56. 2019
The potential of reducing AST testing in hospital settings. 64:57-59. 2019
Pre-analytical variables affecting discordant results on repeat sample testing for cardiac troponin I. 63:158-160. 2019
The importance of tumour marker dual reporting during method transition: PSA high-dose hook effect detected. 61:45-46. 2018
Differences in total PSA results within and between manufacturers. 60:91-92. 2018
The potential role of a turbidimetric heart-type fatty acid-binding protein assay to aid in the interpretation of persistently elevated, non-changing, cardiac troponin I concentrations. 58:53-59. 2018
Should detectable cardiac troponin concentrations in a healthy population be the only criterion for classifying high-sensitivity cardiac troponin assays?. 56:1-3. 2018
Candidate recommendations for protein electrophoresis reporting from the Canadian Society of Clinical Chemists Monoclonal Gammopathy Working Group. 51:10-20. 2018
Effect of a low glycemic index diet versus a high-cereal fibre diet on markers of subclinical cardiac injury in healthy individuals with type 2 diabetes mellitus: An exploratory analysis of a randomized dietary trial. 50:1104-1109. 2017
National Survey of Adult and Pediatric Reference Intervals in Clinical Laboratories across Canada: A Report of the CSCC Working Group on Reference Interval Harmonization. 50:925-935. 2017
Rates of inappropriate laboratory test utilization in Ontario. 50:822-827. 2017
Book Review. 50:737-737. 2017
A statistical method to calculate blood contamination in the measurement of salivary hormones in healthy women. 50:436-439. 2017
Can 100 papers over 50 years tell the story of a scientific journal?. 50:1-5. 2017
Lot change for reagents and calibrators. 49:1211-1212. 2016
Reality check for cardiac troponin testing – Sometimes the result is wrong. 49:1107-1108. 2016
Statistical issues with the determination of the troponin 99th percentile – Not just a problem for troponin?. 49:1105-1106. 2016
Carryover: More than just a major hangover for the clinical laboratory. 49:735-736. 2016
Relationship of N-Terminal fragment of Pro-B-Type Natriuretic Peptide and copeptin with erythrocytes-related parameters: A population-based study. 49:651-656. 2016
Error detection in routine clinical chemistry laboratory test results. 49:199-200. 2016
Evaluation of natriuretic peptide recommendations in heart failure clinical practice guidelines. 49:8-15. 2016
Clinical Biochemistry 2015 year in review: Material not for the faint of heart. 48:1211-1212. 2015
Upcoming biomarkers for the diagnosis of Kawasaki disease: A review. 48:1188-1194. 2015
Sex-specific cutoffs for cardiac troponin using high-sensitivity assays — Is there clinical equipoise?. 48:749-750. 2015
What is in that sample ? A pertinent question when assessing quality for patient laboratory results and beyond. 48:465-466. 2015
Laboratory challenges in primary aldosteronism screening and diagnosis. 48:377-387. 2015
An approach to rule-out an acute cardiovascular event or death in emergency department patients using outcome-based cutoffs for high-sensitivity cardiac troponin assays and glucose. 48:282-287. 2015
Combining presentation high-sensitivity cardiac troponin I and glucose measurements to rule-out an acute myocardial infarction in patients presenting to emergency department with chest pain. 48:288-291. 2015
Evidence based application of BNP/NT-proBNP testing in heart failure. 48:236-246. 2015
Clinical Biochemistry year in review — The clinical “good”, the analytical “bad”, and the “ugly” laboratory practices. 47:255-256. 2014
Canadian Institutes of Health Research dissemination grant on high-sensitivity cardiac troponin. 47:155-157. 2014
Metrics for identifying errors related to pre-analytical sample handling. 47:989-990. 2014
Assessing the necessity of including a crossover period with dual reporting when changing total prostate-specific antigen methods. 47:897-900. 2014
Genomics and epigenomics in pediatric oncology and clinical laboratory genetics. 47:731-732. 2014
Promoting healthy growth and nutrition in preterm infants: A challenge for clinicians and researchers. 47:711-713. 2014
The challenge of establishing, growing and sustaining a large biobank. 47:239-244. 2014
Quality control material testing and the importance of “treating it like a patient's sample”. 47:147-149. 2014
Response to comment on: Dysregulated expression of T cell immunoglobulin and mucin domain 3 is associated with the disease severity and the outcome of patients with spontaneous intracerebral hemorrhage. 47:146-146. 2014
Evaluation of a commercially available carbohydrate deficient transferrin kit to detect beta-2-transferrin in cerebrospinal fluid using capillary electrophoresis. 46:1770-1773. 2013
Of stroke and biomarkers: The elusive quest for a clinical biomarker panel. 46:705-706. 2013
Role of the laboratory in diabetes diagnosis and screening—The 2013 CDA CPGs. 46:707-709. 2013
A step closer in reducing hemolysis in blood samples collected in the emergency department. 46:565-565. 2013
Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population. 46:5-9. 2013
Editorial comment on Leung et al.: CUB and zona pellucida-like domain-containing protein 1 (CUZD1): A novel serological biomarker for ovarian cancer. 45:1547-1547. 2012
Position statement of the Canadian Society of Clinical Chemists and Canadian Association of Medical Biochemists on hemoglobin A1c measurement and reporting. 45:1036-1037. 2012
Assessment of a four hour delay for urine samples stored without preservatives at room temperature for urinalysis. 45:856-858. 2012
Improving serological test ordering patterns for the diagnosis of celiac disease through clinical laboratory audit of practice. 45:455-459. 2012
Whether it is personalized, precision, or mechanistic medicine - the clinical laboratory has a role. 45:384-384. 2012
Statistical and analytical approaches for assessing biomarkers: New approaches, new technologies, with the same-old rigor for evaluation. 45:187-188. 2012
The ABCs of clinical biochemistry. 45:1-2. 2012
Autism spectrum disorder: When biochemical and genetic profiles don't match — Is sample size and selection bias the culprit?. 44:1358-1358. 2011
Cardiac troponin testing in the acute care setting: Ordering, reporting, and high sensitivity assays—An update from the Canadian society of clinical chemists (CSCC). 44:1273-1277. 2011
Comparison of monomeric prolactin levels following macroprolactin precipitation by PEG6000 and PEG8000. 44:1183-1183. 2011
High sensitivity troponin T concentrations in patients undergoing noncardiac surgery: A prospective cohort study. 44:1021-1024. 2011
Early standardization of high sensitivity troponin T reporting - a lost opportunity. 44:758-759. 2011
High sensitivity cardiac troponin concentration cutoffs—is a healthy population the right reference population for those with underlying cardiac disease?. 43:1037-1038. 2010
Identification of myocardial injury in the emergency setting. 43:539-544. 2010
The use of a cytokine panel to define the long-term risk stratification of heart failure/death in patients presenting with chest pain to the emergency department. 43:505-507. 2010
Pediatric critical values: Laboratory–pediatrician discourse. 42:1658-1661. 2009
Biochip arrays for the discovery of a biomarker surrogate in a phase I/II study assessing a novel anti-metastasis agent. 42:1162-1165. 2009
Bone turnover markers in the management of postmenopausal osteoporosis. 42:929-942. 2009
Intra-individual variability in troponin T concentration in dialysis patients. 42:991-995. 2009
PAPP-A as a marker of increased long-term risk in patients with chest pain. 42:1012-1018. 2009
The (mis) use of bone resorption markers in the context of bisphosphonate exposure, dental surgery and osteonecrosis of the jaw. 42:1194-1196. 2009
Laboratory defined critical value limits: How do hospital physicians perceive laboratory based critical values?. 42:766-770. 2009
Clinical implication of the difference between transcutaneous bilirubinometry and total serum bilirubin for the classification of newborns at risk of hyperbilirubinemia. 42:176-179. 2009
Cytokine elevations in acute coronary syndrome and ovarian cancer: A mechanism for the up-regulation of the acute phase proteins in these different disease etiologies. 41:607-610. 2008
Vascular versus myocardial dysfunction in acute coronary syndrome: Are the adhesion molecules as powerful as NT-proBNP for long-term risk stratification?. 41:436-439. 2008
A systematic review of BNP as a predictor of prognosis in persons with coronary artery disease. 41:260-265. 2008
Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: A systematic review. 41:250-259. 2008
Evaluating the evidence for assessing BNP and NT-proBNP levels. 41:227-230. 2008
Evidence for the use of B-type natriuretic peptides for screening asymptomatic populations and for diagnosis in primary care. 41:240-249. 2008
Monitoring the response to pharmacologic therapy in patients with stable chronic heart failure: Is BNP or NT-proBNP a useful assessment tool?. 41:266-276. 2008
Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP. 41:231-239. 2008
Use of an interferon-gamma based assay to assess bladder cancer patients treated with intravesical BCG and exposed to tuberculosis. 40:913-915. 2007
Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure. 40:326-329. 2007
Incomplete pediatric reference intervals for the management of patients with inborn errors of metabolism. 39:595-599. 2006
Pediatric reference intervals: Critical gap analysis and establishment of a national initiative. 39:559-560. 2006
Detection of ischemic myocardial injury in patients with normal, or moderately elevated, serum CK and AST actitivities (reprinted from Clinical Biochemistry, 1982, vol. 15, pg. 138-140). 39:468-470. 2006
Sweat collection for testing in Canadian Cystic Fibrosis Centers, is it optimal?. 38:934-937. 2005
Challenges of implementing Point-of-Care Testing (POCT) glucose meters in a pediatric acute care setting. 37:811-817. 2004
Hyperhomocysteinemia and its role in the development of atherosclerosis. 36:431-441. 2003
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. 36:1-7. 2003
Do wine polyphenols modulate p53 gene expression in human cancer cell lines?. 34:415-420. 2001
Moderate alcohol consumption: the gentle face of Janus. 32:505-518. 1999
Monthly intra-individual variation in lipids over a 1-year period in 22 normal subjects. 32:381-389. 1999
Multicenter evaluation of an amperometric immunosensor for plasma fatty acid-binding protein:. 32:229-231. 1999
Correspondence. 31:117-118. 1998
Reverse Cholesterol Transport—A Review of the Process and Its Clinical Implications. 30:517-525. 1997
Mutations in cholesteryl ester transfer protein and hepatic lipase in a North American population. 30:413-418. 1997
Monthly intra-individual variation in lipoprotein(a) in 22 normal subjects over 12 months. 30:163-170. 1997
Prognostic value of immunofluorometrically quantifed P53 protein in ovarian carcinoma. 28:341-341. 1995
Evaluation of a turbidimetric procedure for apolipoproteins A1 and B on the Ciba Corning 550 EXPRESS. 26:477-482. 1993
An overview of the conference. 26:1-3. 1993
Role of the laboratory in meeting the needs of critical care. 26:8-10. 1993
A quantitative physicochemical approach to acid-base physiology. 23:189-195. 1990
The significance of matrix effects on the measurement of lactate dehydrogenase (LD) activity using kodak dry slide technology in the ontario laboratory proficiency testing program. 23:179-181. 1990
A quantitative physicochemical approach to acid-base physiology. 23:261-266. 1990
Regulation of carnosine metabolism: The subcellular localization of carnosinase in liver. 21:315-318. 1988
Methods of therapeutic drug analysis. 19:113-121. 1986
The role of the laboratory in acute poisoning: case histories. 19:127-131. 1986
Porphyria cutanea tarda, or the uroporphyrinogen decarboxylase deficiency diseases. 19:3-15. 1986
Colorimetric determination of acetaminophen. 16:220-221. 1983
Determination of tricyclic antidepressant drugs by gas chromatography with the use of a capillary column. 16:94-97. 1983
Detection of ischemic myocardial injury in patients with normal, or moderately elevated, serum CK and AST actitivities. 15:138-140. 1982
Identification of hemoglobin E by the isopropanol solubility test. 13:146-148. 1980
Identification of misused drugs in the clinical laboratory. 13:184-184. 1980
Correlation of serum enzymes and isoenzymes myocardial damage and autopsy findings. 12:217-218. 1979
Heterogeneity of serum cholinesterase. 12:223-224. 1979
Laboratory diagnosis of HB CC-α-thalassemia. 12:157-158. 1979
Motilin, human pancreatic polypeptide (HPP) and gastrin plasma concentrations in fasting subjects. 12:109-117. 1979
Estimation of theophylline in plasma by thin-layer chromatography. 11:42-45. 1978
A study of the salivary glycoprotein in cystic fibrosis patients and controls: fucose incorporation and protein pattern. 10:153-155. 1977
Estimation of amitriptyline and its metabolites in serum and urine by GLC using nitrogen-specific detector. 9:247-251. 1976
Relationship between serum cholinesterase and low density lipoproteins in children with nephrotic syndrome. 8:103-107. 1975
Variations in ovarian steroid levels during the luteal phase of the menstrual cycle. 8:234-239. 1975
A rapid method for the radioimmunoassay of urinary aldosterone. 6:285-294. 1973
Serum gamma glutamyl transpeptidase in liver disorders. 6:41-45. 1973
Assay of plasma renin activity using commercially available reagents. 5:251-265. 1972

Clinical Biochemistry Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)